Update on ECHA’s Candidate List of SVHC
ECHA has updated its Candidate List of SVHCs with 4 new substances. 4-MBC, which is used in cosmetic products as an UV-filter is one of the new entries.
Picture of Marta Pinto

Marta Pinto

Regulatory Affairs Associate


Substances of Very High Concern (SVHCs) are substances that may have serious effects on human health and the environment. SVHCs are mainly substances classified as carcinogenic, mutagenic or toxic to reproduction and substances with persistent and bio-accumulative characteristics. Endocrine disrupting chemicals are also of concern.

Once a substance is officially identified in the European Union (EU) as being of very high concern, it is added to the ‘Candidate List’, which indicates to consumers and industry which are the chemicals identified as SVHCs. Producers or importers of articles containing SVHCs above 0.1% (weight by weight), must inform costumers and consumers about the presence of the substance and how to use it safely. If consumers request this information, companies must also inform them.

Producers and importers need to notify ECHA if their article contains a Candidate List substance within six months from the date it has been included in the list. Suppliers of these substances (supplied on their own or in mixtures) must provide a safety data sheet to their costumers.

According to the Waste Framework Directive (Directive 2008/98/EC, Article 9), the notification to ECHA of articles containing SVHCs on the Candidate List (at a concentration above 0.1% w/w) is published in the SCIP (Substances Of Concern In Articles as such or in complex objects (Products)) database.


This month, the European Chemicals Agency (ECHA) Candidate List of SVHCs has been updated with 4 new substances and now contains 233 entries for chemicals that can harm people or the environment.

The following entries were added to the list:

  • 6,6′-di-tert-butyl-2,2′-methylenedi-p-cresol (CAS number: 119-47-1) – used in rubbers, lubricants, adhesives, inks, fuels.
  • tris(2-methoxyethoxy)vinylsilane (CAS number: 1067-53-4) – used in rubbers, plastics, sealants.
  • (±)-1,7,7-trimethyl-3-[(4-methylphenyl)methylene]bicyclo[2.2.1]heptan-2-one covering any of the individual isomers and/or combinations thereof (4-MBC) – used in cosmetics.
  • S-(tricyclo(,6)deca-3-en-8(or 9)-yl O-(isopropyl or isobutyl or 2-ethylhexyl) O-(isopropyl or isobutyl or 2-ethylhexyl) phosphorodithioate (CAS number: 255881-94-8) – used in lubricants, greases.

The first two substances were added because they are toxic for reproduction, and the fourth compound is persistent, bioaccumulative and toxic, being harmful for the environment.

The substance 4-MBC is used in cosmetics and has been added to the Candidate List because it has hormone-disrupting properties in humans. According to the Cosmetics Regulation (No. 1223/2009), 4-MBC is included in the list of UV filters allowed in cosmetic products (Annex VI, entry 18). 4-Methylbenzylidene Camphor can be used as an UV filter in sunscreen products at concentrations up to 4% in ready for use preparation. The European Commission Scientific Committee on Consumer Safety (SCCS) published a preliminary opinion on 4-MBC and stated that it “cannot concluded on the safety of 4-MBC, because the information provided is insufficient to fully evaluate potential genotoxicity”. (see previous post)

In the future, these substances may be included in the ‘Authorisation List’, which means that the use of such substance is prohibited unless a company receives an authorization from the European Commission to continue its use.

As advised by ECHA, companies are urged to check their legal obligations relating to the safe use of these substances and to seek substitution of substances included in the SVHC Candidate List by safer alternatives.

If you need more information regarding this subject, feel free to contact us at  info@criticalcatalyst.com.


  1. Regulation (EC) No 1223/2009 of the European Parliament and of the Council of 30 November 2009 on cosmetic products
  2. Scientific Committee on Consumer Safety (SCCS). Opinion on 4-MEthylbenzylidene camphor (4-MBC). SCCS/1640/21. Preliminary version. 2021.
  3. Four hazardous chemicals added to the Candidate List. ECHA/NR/22/01. European Chemicals Agency (ECHA). 2022


medical devices

Safety Reporting in Clinical Investigations: a Gap Analysis of Guidance Documents 

Safety reporting in clinical investigations of medical devices shall be performed in line with Article 80(2) of the EU MDR. On May 2020, it was published the MDCG 2020-10/1, outlining the procedures for safety reporting in clinical investigations of medical devices under the EU MDR. However, on October 2022 the Medical Device Coordination Group (MDCG) published an updated version of the MDCG 2020-10/1, the MDCG 2020-10/1 Rev 1. This article highlights the updates included in the new revision, analysing the gaps between both documents.

Read More »
medical devices

Roles and Responsibilities of an Authorised Representative under EU MDR and IVDR 

If a medical device manufacturer is not established in a Member State, the devices can only be placed on the Union market if the manufacturer designates an authorised representative. The authorised representative plays a pivotal role in ensuring the compliance of the devices with EU regulation, serving as point of contact. The obligations and responsibilities of authorised representative are outlined on Article 11 of both MDR and IVDR, but clarification of relevant requirements is described in MDCG 2022-16 of October 2022.

Read More »
medical devices

Understanding the ISO Standards Lifecycle

ISO Standards cover a huge range of activities, representing the distilled wisdom of people with expertise in their subject matter and providing the regulators with a sound basis to develop better legislation. ISO Standards are diverse, addressing from the shoe size we wear to the quality of air we breathe. The medical device sector is no exception. ISO has many International Standards and guidance documents aimed at helping the sector ensure safe and effective medical devices while meeting the multitude of national, regional and international regulatory requirements. But how exactly is a Standard developed, reviewed and withdraw?

Read More »
medical devices

Amendments to the Transitional Provisions of the European Union MDR and IVDR

The proposed amendments aim to maintain patients’ access to a wide range of medical devices while ensuring the transition to the new framework. The ammendments proposal aims to extend the current transition period (Article 120 of the MDR), and it also deletes the ‘sell-off’ deadlines of both MDR and IVDR. The extension is staggered depending on the risk class of the device – until December 2027 for high-risk devices and December 2028 for medium and lower-risk devices.

Read More »
medical devices

EU MDR – Proposal for Extension of Transition Period

The transition to MDR has been slower than anticipated by the European Commission. Insufficient capacity of notified bodies and the low level of preparedness of manufacturers led to a proposal for extension of current MDR transition period with deadlines depending on the risk class of the devices.

Read More »
medical devices

MDCG 2022-18 – EU MDR Article 97

EU MDR Article 97 may be a temporary solution to avoid disruption of supply of Medical Devices on the EU Market. The MDCG 2022-18 presents a uniform approach for application of MDR Article 97 on non-compliant legacy devices under the conditions set by the competent authorities, while limiting the impact on the supply of safe and effective devices.

Read More »
cosmetic products

EU to set Labelling Requirements for 56 additional Fragrance Allergens in Cosmetic Products

World Trade Organization (WTO) has been notified by the European Commission of a draft amendment to Regulation (EC) No 1223/2009 as regards labelling of fragrance allergens in Cosmetic Products. The proposed date of adoption of the new regulation is expected to be in the first half of 2023 and the propose date of entry in force 20 days from the publication in the Official Journal of the European Union.

Read More »
cosmetic products

New Amendments to the European Cosmetics Regulation – CMR Substances

The European Commission published the Commission Regulation (EU) 2022/1531, which amends Regulation (EC) No 1223/2009 in regards to the use in cosmetic products of certain substances classified as CMR. This amendment introduces new entries to Annex II and Annex III and revises an entry to Annex V to Regulation (EC) No 1223/2009.

Read More »